Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

IMPORTANCE: Anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms. People living with HIV (PLWH) have routinely been excluded from ICB clinical trials, thus inhibiting broad im...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuss, Joshua E., Stern, Diana, Foster, Jared C., Ramaswami, Ramya, Lurain, Kathryn, Chen, Helen X., Streicher, Howard, Kem, Ravie, Little, Richard F., Sharon, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709086/
https://www.ncbi.nlm.nih.gov/pubmed/33258905
http://dx.doi.org/10.1001/jamanetworkopen.2020.27110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709086/
https://www.ncbi.nlm.nih.gov/pubmed/33258905
http://dx.doi.org/10.1001/jamanetworkopen.2020.27110

Ejemplares similares